Immunology
Zeile 2: | Zeile 2: | ||
'''Antibody-dependent enhancement''' | '''Antibody-dependent enhancement''' | ||
− | + | {{ttp|p=32504046|t=2020. Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures.|pdf=|usr=007}} | |
{{ttp|p=32092539|t=2020. Is COVID-19 receiving ADE from other coronaviruses?|pdf=|usr=}} | {{ttp|p=32092539|t=2020. Is COVID-19 receiving ADE from other coronaviruses?|pdf=|usr=}} | ||
{{tp|p=32268188|t=ä. It is too soon to attribute ADE to COVID-19 |pdf=|usr=}} | {{tp|p=32268188|t=ä. It is too soon to attribute ADE to COVID-19 |pdf=|usr=}} | ||
Zeile 11: | Zeile 11: | ||
{{tp|p=32438257|t=2020. SARS-CoV-2 and enhancing antibodies |pdf=|usr=}} | {{tp|p=32438257|t=2020. SARS-CoV-2 and enhancing antibodies |pdf=|usr=}} | ||
{{ttp|p=32408068|t=2020. What about the original antigenic sin of the humans versus SARS-CoV-2?|pdf=|usr=}}''the term «original antigenic sin» (OAS) was coined by T. Francis Jr at the Michigan University in the late 1950s to describe patterns of antibody response to influenza vaccination...'' | {{ttp|p=32408068|t=2020. What about the original antigenic sin of the humans versus SARS-CoV-2?|pdf=|usr=}}''the term «original antigenic sin» (OAS) was coined by T. Francis Jr at the Michigan University in the late 1950s to describe patterns of antibody response to influenza vaccination...'' | ||
+ | {{tp|p=32436320|t=2020. The role of SARS-CoV-2 antibodies in COVID-19: Healing in most, harm at times.|pdf=|usr=007}} | ||
+ | {{tp|p=32506725|t=2020. Dengue Fever, COVID-19 (SARS-CoV-2), and Antibody-Dependent Enhancement (ADE): A Perspective.|pdf=|usr=007}} | ||
+ | |||
+ | |||
+ | '''Herd immunity''' | ||
+ | {{tp|p=32438622|t=2020. Dynamics of Population Immunity Due to the Herd Effect in the COVID-19 Pandemic.|pdf=|usr=007}} | ||
+ | {{tp|p=32391855|t=2020. COVID-19 and Postinfection Immunity: Limited Evidence, Many Remaining Questions.|pdf=|usr=007}} | ||
+ | {{tp|p=32510562|t=2020. Long-term and herd immunity against SARS-CoV-2: implications from current and past knowledge.|pdf=|usr=007}} | ||
+ | {{tp|p=32418947|t=2020. Does immune privilege result in recovered patients testing positive for COVID-19 again?|pdf=|usr=007}} | ||
+ | {{tp|p=32372779|t=2020. Do you become immune once you have been infected?|pdf=|usr=}} | ||
+ | |||
+ | '''Neutralizing antibodies''' | ||
+ | {{tp|p=32454513|t=2020. Human neutralizing antibodies elicited by SARS-CoV-2 infection.|pdf=|usr=007}} | ||
+ | {{tp|p=32454512|t=2020. A human neutralizing antibody targets the receptor binding site of SARS-CoV-2.|pdf=|usr=007}} | ||
+ | {{tp|p=32497196|t=2020. Neutralizing Antibodies Responses to SARS-CoV-2 in COVID-19 Inpatients and Convalescent Patients.|pdf=|usr=007}} | ||
+ | {{ttp|p=32073157|t=2020. Antibodies to coronaviruses are higher in older compared with younger adults and binding antibodies are more sensitive than neutralizing antibodies in identifying coronavirus?associated illnesses |pdf=|usr=}} | ||
'''Innate sensing of infection''' | '''Innate sensing of infection''' | ||
Zeile 19: | Zeile 35: | ||
{{tp|p=32248387|t=ä. Use of DAMPs and SAMPs as Therapeutic Targets or Therapeutics: A Note of Caution |pdf=|usr=}} | {{tp|p=32248387|t=ä. Use of DAMPs and SAMPs as Therapeutic Targets or Therapeutics: A Note of Caution |pdf=|usr=}} | ||
{{ttp|p=32407669|t=ä. Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients |pdf=|usr=}} | {{ttp|p=32407669|t=ä. Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients |pdf=|usr=}} | ||
+ | {{tp|p=32456409|t=2020. A theory on SARS-COV-2 susceptibility: reduced TLR7-activity as a mechanistic link between men, obese and elderly.|pdf=|usr=007}} | ||
+ | {{ttp|p=32156572|t=2020. Viroporins and inflammasomes: A key to understand virus-induced inflammation |pdf=|usr=}} | ||
'''nk cells''' | '''nk cells''' | ||
{{tp|p=32382127|t=ä. NKG2A and COVID-19: another brick in the wall |pdf=|usr=}} | {{tp|p=32382127|t=ä. NKG2A and COVID-19: another brick in the wall |pdf=|usr=}} | ||
+ | {{tp|p=32344314|t=2020. Innate immunity in COVID-19 patients mediated by NKG2A receptors, and potential treatment using Monalizumab, Cholroquine, and antiviral agents |pdf=|usr=}} | ||
+ | |||
'''integrative work''' | '''integrative work''' | ||
Zeile 30: | Zeile 50: | ||
{{ttp|p=C7200337|t=ä. Immunology of COVID-19: current state of the science |pdf=|usr=}} | {{ttp|p=C7200337|t=ä. Immunology of COVID-19: current state of the science |pdf=|usr=}} | ||
{{tp|p=32505227|t=2020. Immunology of COVID-19: Current State of the Science.|pdf=|usr=007}} | {{tp|p=32505227|t=2020. Immunology of COVID-19: Current State of the Science.|pdf=|usr=007}} | ||
+ | {{tp|p=32469225|t=2020. COVID-19 and the immune system.|pdf=|usr=007}} | ||
+ | {{ttp|p=32436629|t=2020. High COVID-19 virus replication rates, the creation of antigen-antibody immune complexes and indirect haemagglutination resulting in thrombosis.|pdf=|usr=007}} | ||
+ | {{tp|p=32507543|t=2020. Spiking Pandemic Potential: Structural and Immunological Aspects of SARS-CoV-2.|pdf=|usr=007}} | ||
+ | {{ttp|p=32504757|t=2020. Protective role of ACE2 and its downregulation in SARS-CoV-2 infection leading to Macrophage Activation Syndrome: Therapeutic implications.|pdf=|usr=007}} | ||
+ | {{tp|p=32493812|t=2020. Role of Aging and the Immune Response to Respiratory Viral Infections: Potential Implications for COVID-19.|pdf=|usr=007}} | ||
+ | {{tp|p=32470151|t=2020. The perplexing question of trained immunity versus adaptive memory in COVID-19.|pdf=|usr=007}} | ||
+ | {{tp|p=32472706|t=2020. The Long-Standing History of Corynebacterium Parvum, Immunity and Viruses.|pdf=|usr=007}} | ||
+ | {{tp|p=32213336|t=ä. SARS-CoV-2: virus dynamics and host response |pdf=|usr=}} | ||
+ | |||
'''covid modulates the immune system''' | '''covid modulates the immune system''' | ||
Zeile 40: | Zeile 69: | ||
{{ttp|p=32236983|t=2020. Why the immune system fails to mount an adaptive immune response to a COVID-19 infection |pdf=|usr=}} | {{ttp|p=32236983|t=2020. Why the immune system fails to mount an adaptive immune response to a COVID-19 infection |pdf=|usr=}} | ||
{{ttp|p=32286536|t=ä. Coronaviruses hijack the complement system |pdf=|usr=}}''host complement activator MASP2 as a target of the N protein of all three viruses'' | {{ttp|p=32286536|t=ä. Coronaviruses hijack the complement system |pdf=|usr=}}''host complement activator MASP2 as a target of the N protein of all three viruses'' | ||
+ | {{tp|p=32463803|t=2020. Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent.|pdf=|usr=007}} | ||
+ | {{tp|p=32492165|t=2020. Clinical and Immune Features of Hospitalized Pediatric Patients With Coronavirus Disease 2019 (COVID-19) in Wuhan, China.|pdf=|usr=007}} | ||
+ | |||
'''mediators''' | '''mediators''' | ||
Zeile 47: | Zeile 79: | ||
{{tp|p=30715745|t=2019. (+)Th17 serum cytokines in relation to laboratory?confirmed respiratory viral infection: A pilot study |pdf=|usr=}} | {{tp|p=30715745|t=2019. (+)Th17 serum cytokines in relation to laboratory?confirmed respiratory viral infection: A pilot study |pdf=|usr=}} | ||
{{tp|p=32414693|t=2020. Interleukin-6 levels in children developing SARS-CoV-2 infection |pdf=|usr=}} | {{tp|p=32414693|t=2020. Interleukin-6 levels in children developing SARS-CoV-2 infection |pdf=|usr=}} | ||
− | + | {{ttp|p=32421281|t=2020. Is there relationship between SARS-CoV 2 and the complement C3 and C4?|pdf=|usr=007}} | |
− | + | {{tp|p=32437622|t=2020. Complement Activation During Critical Illness: Current Findings and an Outlook in the Era of COVID-19.|pdf=|usr=007}} | |
'''plasmacytoid dendritic cells''' | '''plasmacytoid dendritic cells''' | ||
Zeile 73: | Zeile 105: | ||
{{tp|p=32379199|t=2020. A Typical Case of Critically Ill Infant of Coronavirus Disease 2019 With Persistent Reduction of T Lymphocytes |pdf=|usr=}} | {{tp|p=32379199|t=2020. A Typical Case of Critically Ill Infant of Coronavirus Disease 2019 With Persistent Reduction of T Lymphocytes |pdf=|usr=}} | ||
{{tp|p=32296069|t=2020. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study |pdf=|usr=}} | {{tp|p=32296069|t=2020. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study |pdf=|usr=}} | ||
− | + | {{tp|p=32407057|t=2020. Peripheral lymphocyte subset monitoring in COVID19 patients: a prospective Italian real-life case series.|pdf=|usr=007}} | |
{{tp|p=32297828|t=2020. Correlation Between Relative Nasopharyngeal Virus RNA Load and Lymphocyte Count Disease Severity in Patients with COVID-19 |pdf=|usr=}} | {{tp|p=32297828|t=2020. Correlation Between Relative Nasopharyngeal Virus RNA Load and Lymphocyte Count Disease Severity in Patients with COVID-19 |pdf=|usr=}} | ||
{{tp|p=32370466|t=2020. Characteristics of peripheral blood leukocyte differential counts in patients with COVID-19 |pdf=|usr=}} | {{tp|p=32370466|t=2020. Characteristics of peripheral blood leukocyte differential counts in patients with COVID-19 |pdf=|usr=}} | ||
Zeile 80: | Zeile 112: | ||
{{tp|p=32361250|t=2020. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients |pdf=|usr=}} | {{tp|p=32361250|t=2020. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients |pdf=|usr=}} | ||
{{ttp|p=32376308|t=2020. Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A systemic review and meta-analysis |pdf=|usr=}} | {{ttp|p=32376308|t=2020. Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A systemic review and meta-analysis |pdf=|usr=}} | ||
+ | {{tp|p=32458561|t=2020. Lymphopenia in COVID-19: Therapeutic opportunities.|pdf=|usr=007}} | ||
+ | {{tp|p=32420610|t=2020. Temporal changes in immune blood cell parameters in COVID-19 infection and recovery from severe infection.|pdf=|usr=007}} | ||
+ | {{tp|p=32470153|t=2020. Characteristics of inflammatory factors and lymphocyte subsets in patients with severe COVID-19.|pdf=|usr=007}} | ||
+ | {{tp|p=32474608|t=2020. Decreased B cells on admission was associated with prolonged viral RNA shedding from respiratory tract in Coronavirus Disease 2019: a case control study.|pdf=|usr=007}} | ||
Zeile 104: | Zeile 140: | ||
{{tp|p=32303696|t=ä. Macrophages: a Trojan horse in COVID-19?|pdf=|usr=}} | {{tp|p=32303696|t=ä. Macrophages: a Trojan horse in COVID-19?|pdf=|usr=}} | ||
{{ttp|p=32376901|t=ä. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages |pdf=|usr=}} | {{ttp|p=32376901|t=ä. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages |pdf=|usr=}} | ||
+ | {{tp|p=32423059|t=2020. Recent Insight into SARS-CoV2 Immunopathology and Rationale for Potential Treatment and Preventive Strategies in COVID-19.|pdf=|usr=007}} | ||
+ | {{tp|p=32485101|t=2020. Vascular Endothelial Growth Factor (VEGF) as a Vital Target for Brain Inflammation during the COVID-19 Outbreak.|pdf=|usr=007}} | ||
+ | {{tp|p=32423917|t=2020. COVID-19 as an Acute Inflammatory Disease.|pdf=|usr=007}} | ||
+ | {{ttp|p=32512289|t=2020. Neutralizing antibodies mediate virus-immune pathology of COVID-19.|pdf=|usr=007}} | ||
+ | {{tp|p=32398875|t=2020. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19.|pdf=|usr=007}} | ||
+ | {{tp|p=32391668|t=2020. [Dynamic inflammatory response in a critically ill COVID-19 patient treated with corticosteroids].|pdf=|usr=007}} | ||
+ | {{ttp|p=32498376|t=2020. Neutrophils and Neutrophil Extracellular Traps Drive Necroinflammation in COVID-19.|pdf=|usr=007}} | ||
+ | {{tp|p=32460357|t=2020. Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China.|pdf=|usr=007}} | ||
Zeile 122: | Zeile 166: | ||
{{tp|p=32382126|t=ä. Protective humoral immunity in SARS-CoV-2 infected pediatric patients |pdf=|usr=}} | {{tp|p=32382126|t=ä. Protective humoral immunity in SARS-CoV-2 infected pediatric patients |pdf=|usr=}} | ||
{{tp|p=32200654|t=2020. Time Kinetics of Viral Clearance and Resolution of Symptoms in Novel Coronavirus Infection |pdf=|usr=}} | {{tp|p=32200654|t=2020. Time Kinetics of Viral Clearance and Resolution of Symptoms in Novel Coronavirus Infection |pdf=|usr=}} | ||
+ | {{tp|p=32476607|t=2020. Delayed specific IgM antibody responses observed among COVID-19 patients with severe progression.|pdf=|usr=007}} | ||
+ | {{tp|p=32449333|t=2020. (+)Ability of the immune system to fight viruses highlighted by cytometry and TCR clonotype assessments: lessons taken prior to COVID-19 virus pandemic outbreak.|pdf=|usr=007}} | ||
+ | {{tp|p=32430094|t=2020. The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection.|pdf=|usr=007}} | ||
+ | {{tp|p=32467617|t=2020. Serum IgA, IgM, and IgG responses in COVID-19.|pdf=|usr=007}} | ||
+ | {{ttp|p=32467616|t=2020. More bricks in the wall against SARS-CoV-2 infection: involvement of gamma9delta2 T cells.|pdf=|usr=007}} | ||
+ | {{ttp|p=32463434|t=2020. Metatranscriptomic Characterization of COVID-19 Identified A Host Transcriptional Classifier Associated With Immune Signaling.|pdf=|usr=007}} | ||
'''secondary autoimmunity''' | '''secondary autoimmunity''' | ||
Zeile 129: | Zeile 179: | ||
{{ttp|p=32314313|t=2020. Is COVID-19 a proteiform disease inducing also molecular mimicry phenomena?|pdf=|usr=}} | {{ttp|p=32314313|t=2020. Is COVID-19 a proteiform disease inducing also molecular mimicry phenomena?|pdf=|usr=}} | ||
{{tp|p=32389543|t=ä. COVID-19 and molecular mimicry: The Columbus? egg?|pdf=|usr=}} | {{tp|p=32389543|t=ä. COVID-19 and molecular mimicry: The Columbus? egg?|pdf=|usr=}} | ||
− | + | {{tp|p=32444414|t=2020. Antibodies against immunogenic epitopes with high sequence identity to SARS-CoV-2 in patients with autoimmune dermatomyositis.|pdf=|usr=007}} | |
Zeile 143: | Zeile 193: | ||
{{ttp|p=32315429|t=ä. Eosinophil count in severe coronavirus disease 2019 (COVID-19) |pdf=|usr=}} | {{ttp|p=32315429|t=ä. Eosinophil count in severe coronavirus disease 2019 (COVID-19) |pdf=|usr=}} | ||
{{tp|p=32315421|t=ä. Response letter to Eosinophil count in severe coronavirus disease 2019 (COVID-19) |pdf=|usr=}} | {{tp|p=32315421|t=ä. Response letter to Eosinophil count in severe coronavirus disease 2019 (COVID-19) |pdf=|usr=}} | ||
+ | {{tp|p=32390402|t=2020. SARS-CoV-2 and Eosinophilia.|pdf=|usr=007}} | ||
− | ''' | + | |
− | {{tp|p= | + | '''microbiome''' |
− | {{ | + | {{tp|p=32497191|t=2020. Alterations of the Gut Microbiota in Patients with COVID-19 or H1N1 Influenza.|pdf=|usr=007}} |
+ | {{ttp|p=32426999|t=2020. Gnotobiotic Rats Reveal That Gut Microbiota Regulates Colonic mRNA of Ace2, the Receptor for SARS-CoV-2 Infectivity.|pdf=|usr=007}} | ||
===007=== | ===007=== | ||
− | + | '''some other papers''' | |
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
{{tp|p=32496715|t=2020. [Etiology of epidemic outbreaks COVID-19 on Wuhan, Hubei province, Chinese People Republic associated with 2019-nCoV (Nidovirales, Coronaviridae, Coronavirinae, Betacoronavirus, Subgenus Sarbecovirus): lessons of SARS-CoV outbreak.]|pdf=|usr=007}} | {{tp|p=32496715|t=2020. [Etiology of epidemic outbreaks COVID-19 on Wuhan, Hubei province, Chinese People Republic associated with 2019-nCoV (Nidovirales, Coronaviridae, Coronavirinae, Betacoronavirus, Subgenus Sarbecovirus): lessons of SARS-CoV outbreak.]|pdf=|usr=007}} | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
{{tp|p=32455617|t=2020. Novel Dynamic Structures of 2019-nCoV with Nonlocal Operator via Powerful Computational Technique.|pdf=|usr=007}} | {{tp|p=32455617|t=2020. Novel Dynamic Structures of 2019-nCoV with Nonlocal Operator via Powerful Computational Technique.|pdf=|usr=007}} | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
{{tp|p=32512133|t=2020. Poor-sleep is associated with slow recovery from lymphopenia and an increased need for ICU care in hospitalized patients with COVID-19: A retrospective cohort study.|pdf=|usr=007}} | {{tp|p=32512133|t=2020. Poor-sleep is associated with slow recovery from lymphopenia and an increased need for ICU care in hospitalized patients with COVID-19: A retrospective cohort study.|pdf=|usr=007}} | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
{{tp|p=32512089|t=2020. Corona virus versus existence of human on the earth: A computational and biophysical approach.|pdf=|usr=007}} | {{tp|p=32512089|t=2020. Corona virus versus existence of human on the earth: A computational and biophysical approach.|pdf=|usr=007}} | ||
{{tp|p=32470223|t=2020. COVID-19: Structural Predictions of Viral Success.|pdf=|usr=007}} | {{tp|p=32470223|t=2020. COVID-19: Structural Predictions of Viral Success.|pdf=|usr=007}} | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
{{tp|p=32423901|t=2020. How covid-19 is accelerating the threat of antimicrobial resistance.|pdf=|usr=007}} | {{tp|p=32423901|t=2020. How covid-19 is accelerating the threat of antimicrobial resistance.|pdf=|usr=007}} | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
{{tp|p=32413176|t=2020. The emergence of methemoglobinemia amidst the COVID-19 pandemic.|pdf=|usr=007}} | {{tp|p=32413176|t=2020. The emergence of methemoglobinemia amidst the COVID-19 pandemic.|pdf=|usr=007}} | ||
− | |||
− | |||
− | |||
− | |||
{{tp|p=32504123|t=2020. COVID-19 research: toxicological input urgently needed!|pdf=|usr=007}} | {{tp|p=32504123|t=2020. COVID-19 research: toxicological input urgently needed!|pdf=|usr=007}} | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
{{tp|p=32412787|t=2020. Bronchoscopy in COVID-19 Patients with Invasive Mechanical Ventilation: A Center Experience.|pdf=|usr=007}} | {{tp|p=32412787|t=2020. Bronchoscopy in COVID-19 Patients with Invasive Mechanical Ventilation: A Center Experience.|pdf=|usr=007}} | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
{{tp|p=32213337|t=ä. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study |pdf=|usr=}} | {{tp|p=32213337|t=ä. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study |pdf=|usr=}} | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
{{tp|p=32215589|t=2020. Antibodies in Infants Born to Mothers With COVID-19 Pneumonia |pdf=|usr=}} | {{tp|p=32215589|t=2020. Antibodies in Infants Born to Mothers With COVID-19 Pneumonia |pdf=|usr=}} | ||
{{tp|p=32360743|t=ä. Lower detection rates of SARS-COV2 antibodies in cancer patients vs healthcare workers after symptomatic COVID-19 |pdf=|usr=}} | {{tp|p=32360743|t=ä. Lower detection rates of SARS-COV2 antibodies in cancer patients vs healthcare workers after symptomatic COVID-19 |pdf=|usr=}} | ||
Zeile 419: | Zeile 218: | ||
{{tp|p=32346093|t=ä. The trinity of COVID-19: immunity, inflammation and intervention |pdf=|usr=}} | {{tp|p=32346093|t=ä. The trinity of COVID-19: immunity, inflammation and intervention |pdf=|usr=}} | ||
{{tp|p=32348636|t=2020. Hyposalivation as a potential risk for SARS-CoV-2 infection: Inhibitory role of saliva |pdf=|usr=}} | {{tp|p=32348636|t=2020. Hyposalivation as a potential risk for SARS-CoV-2 infection: Inhibitory role of saliva |pdf=|usr=}} | ||
− | |||
− | |||
− | |||
{{tp|p=32235915|t=ä. COVID-19: a new challenge for human beings |pdf=|usr=}} | {{tp|p=32235915|t=ä. COVID-19: a new challenge for human beings |pdf=|usr=}} | ||
{{ttp|p=32359201|t=2020. The first, holistic immunological model of COVID-19: implications for prevention, diagnosis, and public health measures |pdf=|usr=}} | {{ttp|p=32359201|t=2020. The first, holistic immunological model of COVID-19: implications for prevention, diagnosis, and public health measures |pdf=|usr=}} | ||
− | |||
{{tp|p=32376309|t=2020. Viral kinetics of SARS-CoV-2 in asymptomatic carriers and presymptomatic patients |pdf=|usr=}} | {{tp|p=32376309|t=2020. Viral kinetics of SARS-CoV-2 in asymptomatic carriers and presymptomatic patients |pdf=|usr=}} | ||
{{tp|p=32132669|t=ä. Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV |pdf=|usr=}} | {{tp|p=32132669|t=ä. Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV |pdf=|usr=}} | ||
{{tp|p=32388390|t=2020. The powerful immune system against powerful COVID-19: A hypothesis |pdf=|usr=}} | {{tp|p=32388390|t=2020. The powerful immune system against powerful COVID-19: A hypothesis |pdf=|usr=}} | ||
{{tp|p=32372807|t=2020. The fever paradox |pdf=|usr=}} | {{tp|p=32372807|t=2020. The fever paradox |pdf=|usr=}} | ||
− |
Version vom 23. Juni 2020, 11:48 Uhr
coviki.org collects the really good Ideas and the scientific Record on Covid-19 Virus.
Antibody-dependent enhancement
32504046 2020. Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures. |
32092539 2020. Is COVID-19 receiving ADE from other coronaviruses? |
32268188 ä. It is too soon to attribute ADE to COVID-19
31826992 2020. Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry |
32317716 ä. The potential danger of suboptimal antibody responses in COVID-19 |
32346094 ä. COVID-19 vaccine design: the Janus face of immune enhancement
32303697 ä. Will we see protection or reinfection in COVID-19?
32438257 2020. SARS-CoV-2 and enhancing antibodies
32408068 2020. What about the original antigenic sin of the humans versus SARS-CoV-2? |
32436320 2020. The role of SARS-CoV-2 antibodies in COVID-19: Healing in most, harm at times.
32506725 2020. Dengue Fever, COVID-19 (SARS-CoV-2), and Antibody-Dependent Enhancement (ADE): A Perspective.
Herd immunity
32438622 2020. Dynamics of Population Immunity Due to the Herd Effect in the COVID-19 Pandemic.
32391855 2020. COVID-19 and Postinfection Immunity: Limited Evidence, Many Remaining Questions.
32510562 2020. Long-term and herd immunity against SARS-CoV-2: implications from current and past knowledge.
32418947 2020. Does immune privilege result in recovered patients testing positive for COVID-19 again?
32372779 2020. Do you become immune once you have been infected?
Neutralizing antibodies
32454513 2020. Human neutralizing antibodies elicited by SARS-CoV-2 infection.
32454512 2020. A human neutralizing antibody targets the receptor binding site of SARS-CoV-2.
32497196 2020. Neutralizing Antibodies Responses to SARS-CoV-2 in COVID-19 Inpatients and Convalescent Patients.
32073157 2020. Antibodies to coronaviruses are higher in older compared with younger adults and binding antibodies are more sensitive than neutralizing antibodies in identifying coronavirus?associated illnesses |
Innate sensing of infection
32291557 ä. SARS-CoV-2-encoded nucleocapsid protein acts as a viral suppressor of RNA interference in cells |
32198201 2020. Coronavirus endoribonuclease targets viral polyuridine sequences to evade activating host sensors
32374430 2020. DC/L-SIGNs of Hope in the COVID-19 Pandemic
32361001 ä. Bioinformatic analysis and identification of single-stranded RNA sequences recognized by TLR7/8 in the SARS-CoV-2, SARS-CoV, and MERS-CoV genomes
32248387 ä. Use of DAMPs and SAMPs as Therapeutic Targets or Therapeutics: A Note of Caution
32407669 ä. Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients |
32456409 2020. A theory on SARS-COV-2 susceptibility: reduced TLR7-activity as a mechanistic link between men, obese and elderly.
32156572 2020. Viroporins and inflammasomes: A key to understand virus-induced inflammation |
nk cells
32382127 ä. NKG2A and COVID-19: another brick in the wall
32344314 2020. Innate immunity in COVID-19 patients mediated by NKG2A receptors, and potential treatment using Monalizumab, Cholroquine, and antiviral agents
integrative work
32205856 2020. COVID-19 infection: the perspectives on immune responses
32359396 ä. A Dynamic Immune Response Shapes COVID-19 Progression
C7064018 ä. Coronavirus infections: Epidemiological, clinical and immunological features and hypotheses
C7200337 ä. Immunology of COVID-19: current state of the science |
32505227 2020. Immunology of COVID-19: Current State of the Science.
32469225 2020. COVID-19 and the immune system.
32436629 2020. High COVID-19 virus replication rates, the creation of antigen-antibody immune complexes and indirect haemagglutination resulting in thrombosis. |
32507543 2020. Spiking Pandemic Potential: Structural and Immunological Aspects of SARS-CoV-2.
32504757 2020. Protective role of ACE2 and its downregulation in SARS-CoV-2 infection leading to Macrophage Activation Syndrome: Therapeutic implications. |
32493812 2020. Role of Aging and the Immune Response to Respiratory Viral Infections: Potential Implications for COVID-19.
32470151 2020. The perplexing question of trained immunity versus adaptive memory in COVID-19.
32472706 2020. The Long-Standing History of Corynebacterium Parvum, Immunity and Viruses.
32213336 ä. SARS-CoV-2: virus dynamics and host response
covid modulates the immune system
32364527 2020. Immune environment modulation in pneumonia patients caused by coronavirus: SARS-CoV, MERS-CoV and SARS-CoV-2
32172672 2020. A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic viruses
32315725 ä. Suppressed T cell-mediated immunity in patients with COVID-19: a clinical retrospective study in Wuhan, China
32355328 ä. Impaired interferon signature in severe COVID-19 |
32375560 2020. SARS-CoV-2-Induced Immune Dysregulation and Myocardial Injury Risk in China: Insights from the ERS-COVID-19 Study
32376308 ä. Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A systemic review and meta-analysis
32236983 2020. Why the immune system fails to mount an adaptive immune response to a COVID-19 infection |
32286536 ä. Coronaviruses hijack the complement system |
32463803 2020. Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent.
32492165 2020. Clinical and Immune Features of Hospitalized Pediatric Patients With Coronavirus Disease 2019 (COVID-19) in Wuhan, China.
mediators
32360285 ä. Type I IFN immunoprofiling in COVID-19 patients
32376393 ä. Interleukin-17A (IL-17A), a key molecule of innate and adaptive immunity, and its potential involvement in COVID-19-related thrombotic and vascular mechanisms |
32305501 ä. The Potential Role of Th17 Immune Responses in Coronavirus Immunopathology and Vaccine-induced Immune Enhancement |
30715745 2019. (+)Th17 serum cytokines in relation to laboratory?confirmed respiratory viral infection: A pilot study
32414693 2020. Interleukin-6 levels in children developing SARS-CoV-2 infection
32421281 2020. Is there relationship between SARS-CoV 2 and the complement C3 and C4? |
32437622 2020. Complement Activation During Critical Illness: Current Findings and an Outlook in the Era of COVID-19.
plasmacytoid dendritic cells
32298486 2020. Plasmacytoid lymphocytes in SARS-CoV-2 infection (Covid-19)
immune cell subpopulations
32282871 ä. Inflammatory Response Cells During Acute Respiratory Distress Syndrome in Patients With Coronavirus Disease 2019 (COVID-19)
32325421 2020. Increased expression of CD8 marker on T-cells in COVID-19 patients
32377375 2020. Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing
32346099 ä. High-dimensional immune profiling by mass cytometry revealed immunosuppression and dysfunction of immunity in COVID-19 patients
32339487 2020. Abnormalities of peripheral blood system in patients with COVID-19 in Wenzhou, China
32361250 2020. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients
32228226 2020. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients
32196410 2020. Hypothesis for potential pathogenesis of SARS-CoV-2 infection?a review of immune changes in patients with viral pneumonia
32333914 ä. A possible role for B cells in COVID-19?: Lesson from patients with Agammaglobulinemia
32344320 ä. The clinical course and its correlated immune status in COVID-19 pneumonia
32325129 ä. The profile of peripheral blood lymphocyte subsets and serum cytokines in children with 2019 novel coronavirus pneumonia
32283159 ä. Lymphocyte subset (CD4+, CD8+) counts reflect the severity of infection and predict the clinical outcomes in patients with COVID-19
32227123 ä. Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia
32343510 2020. COVID-19: are T lymphocytes simply watching?
32379887 ä. T cell subset counts in peripheral blood can be used as discriminatory biomarkers for diagnosis and severity prediction of COVID-19
32297671 2020. Relationships among lymphocyte subsets, cytokines, and the pulmonary inflammation index in coronavirus (COVID-19) infected patients
32352397 2020. The hemocyte counts as a potential biomarker for predicting disease progression in COVID-19: a retrospective study
32379199 2020. A Typical Case of Critically Ill Infant of Coronavirus Disease 2019 With Persistent Reduction of T Lymphocytes
32296069 2020. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study
32407057 2020. Peripheral lymphocyte subset monitoring in COVID19 patients: a prospective Italian real-life case series.
32297828 2020. Correlation Between Relative Nasopharyngeal Virus RNA Load and Lymphocyte Count Disease Severity in Patients with COVID-19
32370466 2020. Characteristics of peripheral blood leukocyte differential counts in patients with COVID-19
32114745 2020. Characteristics of peripheral blood leukocyte differential counts in patients with COVID-19
32377375 2020. Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing
32361250 2020. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients
32376308 2020. Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A systemic review and meta-analysis |
32458561 2020. Lymphopenia in COVID-19: Therapeutic opportunities.
32420610 2020. Temporal changes in immune blood cell parameters in COVID-19 infection and recovery from severe infection.
32470153 2020. Characteristics of inflammatory factors and lymphocyte subsets in patients with severe COVID-19.
32474608 2020. Decreased B cells on admission was associated with prolonged viral RNA shedding from respiratory tract in Coronavirus Disease 2019: a case control study.
t cell exhaustion
32249845 ä. Fighting COVID-19 exhausts T cells
32203188 ä. Functional exhaustion of antiviral lymphocytes in COVID-19 patients |
32203186 ä. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients |
32203188 2020. Functional exhaustion of antiviral lymphocytes in COVID-19 patients |
32203186 2020. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients |
immunopathology
32371101 ä. The correlation between SARS-CoV-2 infection and rheumatic disease
32205186 2020. COVID-19 infection and rheumatoid arthritis: Faraway, so close!
32308263 2020. CoViD-19 Immunopathology and Immunotherapy
32320677 ä. Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure
32161940 ä. Dysregulation of immune response in patients with COVID-19 in Wuhan, China
32282863 ä. Molecular immune pathogenesis and diagnosis of COVID-19
32321823 2020. COVID-19: an Immunopathological View
32273594 ä. COVID-19: immunopathology and its implications for therapy
32303696 ä. Macrophages: a Trojan horse in COVID-19?
32376901 ä. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages |
32423059 2020. Recent Insight into SARS-CoV2 Immunopathology and Rationale for Potential Treatment and Preventive Strategies in COVID-19.
32485101 2020. Vascular Endothelial Growth Factor (VEGF) as a Vital Target for Brain Inflammation during the COVID-19 Outbreak.
32423917 2020. COVID-19 as an Acute Inflammatory Disease.
32512289 2020. Neutralizing antibodies mediate virus-immune pathology of COVID-19. |
32398875 2020. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19.
32391668 2020. [Dynamic inflammatory response in a critically ill COVID-19 patient treated with corticosteroids].
32498376 2020. Neutrophils and Neutrophil Extracellular Traps Drive Necroinflammation in COVID-19. |
32460357 2020. Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China.
antiviral immune response
32280952 ä. Good IgA bad IgG in SARS-CoV-2 infection?
32353870 2020. The many faces of the anti-COVID immune response
32358956 ä. Longitudinal Change of SARS-Cov2 Antibodies in Patients with COVID-19
31981224 2020. Coronavirus infections and immune responses
32198005 2020. A case of COVID-19 and pneumonia returning from Macau in Taiwan: Clinical course and anti-SARS-CoV-2 IgG dynamic
32284614 ä. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19
32355329 ä. SARS-CoV-2-reactive T cells in patients and healthy donors
32346091 ä. Neutralizing antibody response in mild COVID-19
32356908 2020. Mathematical modeling of interaction between innate and adaptive immune responses in COVID-19 and implications for viral pathogenesis
32343415 2020. Long-term coexistence of SARS-CoV-2 with antibody response in COVID-19 patients |
32330332 2020. SARS-CoV-2 infection in children - Understanding the immune responses and controlling the pandemic
32267987 2020. Immune responses and pathogenesis of SARS?CoV?2 during an outbreak in Iran: Comparison with SARS and MERS
32348715 2020. B Cells, Viruses, and the SARS-CoV-2/COVID-19 Pandemic of 2020
32382126 ä. Protective humoral immunity in SARS-CoV-2 infected pediatric patients
32200654 2020. Time Kinetics of Viral Clearance and Resolution of Symptoms in Novel Coronavirus Infection
32476607 2020. Delayed specific IgM antibody responses observed among COVID-19 patients with severe progression.
32449333 2020. (+)Ability of the immune system to fight viruses highlighted by cytometry and TCR clonotype assessments: lessons taken prior to COVID-19 virus pandemic outbreak.
32430094 2020. The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection.
32467617 2020. Serum IgA, IgM, and IgG responses in COVID-19.
32467616 2020. More bricks in the wall against SARS-CoV-2 infection: involvement of gamma9delta2 T cells. |
32463434 2020. Metatranscriptomic Characterization of COVID-19 Identified A Host Transcriptional Classifier Associated With Immune Signaling. |
secondary autoimmunity
32292901 2020. Pathogenic priming likely contributes to serious and critical illness and mortality in COVID-19 via autoimmunity
32220633 2020. Could Sars-coronavirus-2 trigger autoimmune and/or autoinflammatory mechanisms in genetically predisposed subjects?
32315487 2020. Clinical and Autoimmune Characteristics of Severe and Critical Cases of COVID-19
32314313 2020. Is COVID-19 a proteiform disease inducing also molecular mimicry phenomena? |
32389543 ä. COVID-19 and molecular mimicry: The Columbus? egg?
32444414 2020. Antibodies against immunogenic epitopes with high sequence identity to SARS-CoV-2 in patients with autoimmune dermatomyositis.
Thymus
32340873 ä. Reply: Thymopoiesis, inflamm-aging, and COVID-19 phenotype
32317217 ä. Role of thymopoiesis and inflamm-aging in COVID-19 phenotype
Eosinopenia, Eosinophilia
32368728 ä. Eosinopenia and elevated C-reactive protein facilitate triage of COVID-19 patients in fever clinic: a retrospective case-control study
32344056 ä. Eosinophil Responses During COVID-19 Infections and Coronavirus Vaccination
32369190 2020. COVID-19, chronic inflammatory respiratory diseases and eosinophils - Observationsfrom reported clinical case series
32315429 ä. Eosinophil count in severe coronavirus disease 2019 (COVID-19) |
32315421 ä. Response letter to Eosinophil count in severe coronavirus disease 2019 (COVID-19)
32390402 2020. SARS-CoV-2 and Eosinophilia.
microbiome
32497191 2020. Alterations of the Gut Microbiota in Patients with COVID-19 or H1N1 Influenza.
32426999 2020. Gnotobiotic Rats Reveal That Gut Microbiota Regulates Colonic mRNA of Ace2, the Receptor for SARS-CoV-2 Infectivity. |
007
some other papers
32496715 2020. [Etiology of epidemic outbreaks COVID-19 on Wuhan, Hubei province, Chinese People Republic associated with 2019-nCoV (Nidovirales, Coronaviridae, Coronavirinae, Betacoronavirus, Subgenus Sarbecovirus): lessons of SARS-CoV outbreak.]
32455617 2020. Novel Dynamic Structures of 2019-nCoV with Nonlocal Operator via Powerful Computational Technique.
32512133 2020. Poor-sleep is associated with slow recovery from lymphopenia and an increased need for ICU care in hospitalized patients with COVID-19: A retrospective cohort study.
32512089 2020. Corona virus versus existence of human on the earth: A computational and biophysical approach.
32470223 2020. COVID-19: Structural Predictions of Viral Success.
32423901 2020. How covid-19 is accelerating the threat of antimicrobial resistance.
32413176 2020. The emergence of methemoglobinemia amidst the COVID-19 pandemic.
32504123 2020. COVID-19 research: toxicological input urgently needed!
32412787 2020. Bronchoscopy in COVID-19 Patients with Invasive Mechanical Ventilation: A Center Experience.
32213337 ä. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study
32215589 2020. Antibodies in Infants Born to Mothers With COVID-19 Pneumonia
32360743 ä. Lower detection rates of SARS-COV2 antibodies in cancer patients vs healthcare workers after symptomatic COVID-19
32292530 2020. Respiratory diseases, allergy and COVID-19 infection. First news from Wuhan
32346093 ä. The trinity of COVID-19: immunity, inflammation and intervention
32348636 2020. Hyposalivation as a potential risk for SARS-CoV-2 infection: Inhibitory role of saliva
32235915 ä. COVID-19: a new challenge for human beings
32359201 2020. The first, holistic immunological model of COVID-19: implications for prevention, diagnosis, and public health measures |
32376309 2020. Viral kinetics of SARS-CoV-2 in asymptomatic carriers and presymptomatic patients
32132669 ä. Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV
32388390 2020. The powerful immune system against powerful COVID-19: A hypothesis
32372807 2020. The fever paradox